NCT07660406 Analyse of Diagnosis Value of Keloid on 68Ga-RGD PET-CT
| NCT ID | NCT07660406 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Keloid |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-08-01 |
| Primary Completion | 2024-10-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 30 participants in total. It began in 2024-08-01 with a primary completion date of 2024-10-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Keloids are often described as benign dermal fibroproliferative lesions characterized by increased growth beyond the boundaries of the original wound margin.Fibroblasts are considered to be the key cellular mediators of fibrogenesis in keloid scars. Thus this prospective study is going to investigate whether 68Ga-RGD PET/CT may provide evidence for diagnosis and evaluate the effectiveness of treatment.
Eligibility Criteria
Inclusion Criteria: \- Patients with a clinical diagnosis of keloids Able to obtain informed consent Exclusion Criteria: \- Pregnant women, children, patients with allergies to contrast media Patients with claustrophobia
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07660406 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Keloid. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07660406 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07660406 currently recruiting?
Yes, NCT07660406 is actively recruiting participants. Contact the research team at 13611093752@163.com for enrollment information.
Where is the NCT07660406 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07660406 clinical trial?
NCT07660406 is sponsored by Peking Union Medical College Hospital. The trial plans to enroll 30 participants.